CCAM
CBPO

Coupland Cardiff Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Coupland Cardiff Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$1.71M Buy
+12,000
New +$1.39M 8.81% 4

Other funds holding CBPO

WP
Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Coupland Cardiff Asset Management's CBPO Position: Q4 2015 in Review

Coupland Cardiff Asset Management opened a new position in China Biologic Products Holdings, Inc. (CBPO) in Q4 2015: 12,000 shares worth $1.71M. The stake represents 8.81% of the portfolio and ranks #4 among its holdings.

114 funds tracked by Wall St. Rank hold CBPO as of Q4 2015.

  • Coupland Cardiff Asset Management held 12,000 shares of China Biologic Products Holdings, Inc. worth $1.71M as of Q4 2015.
  • China Biologic Products Holdings, Inc. was a new Coupland Cardiff Asset Management position in Q4 2015.
  • China Biologic Products Holdings, Inc. made up 8.81% of Coupland Cardiff Asset Management's portfolio in Q4 2015, its #4 holding.
  • 114 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2015.

Based on Coupland Cardiff Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.